A Crossover Study to Evaluate the Efficacy of Simvastatin in Elevating HDL-C Levels in Patients With Type 2 Diabetes (0733-216)(COMPLETED)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Balanced, Three-Way Crossover Study to Evaluate the Efficacy of Simvastatin Therapy in Elevating HDL-C Levels in Patients With Type 2 Diabetic Dyslipidemia and Low HDL-C
Actual Study Start Date :
July 26, 2001
Actual Primary Completion Date :
October 4, 2002
Actual Study Completion Date :
October 4, 2002
Resource links provided by the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 75 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patient has stable Type 2 diabetes mellitus at Visit 1.
Patient meets screening criteria based on Visit 1 lab tests
Patient is pregnant, breastfeeding, or at risk of becoming pregnant
Patient has heart disease, uncontrolled high blood pressure, or other significant disease
Patient is taking prohibited medication(s) and is unable to stop taking them for the duration of the study